Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 4,648

Document Document Title
WO/2019/062848A1
The present invention discloses an N-(substituted sulfonyl)benzamide derivative, a preparation method therefor, and a pharmaceutical use thereof. Specifically, the present invention discloses an N-(substituted sulfonyl)benzamide derivati...  
WO/2019/054805A1
The present invention relates to a chemically amplified photoresist composition comprising an alkali-soluble resin and a polymeric photoacid generator having a preset structure, to a photoresist pattern generated from the chemically ampl...  
WO/2019/049918A1
The present invention relates to a method of mono-alkylating a piperidine nitrogen in a piperidine derivative with a deuterated lower-alkyl, which comprises protecting the piperidine nitrogen with an aralkyl protective group, lower-alkyl...  
WO/2019/050120A1
The present invention relates to a photoacid generator and a chemically amplified positive photoresist composition for a thick film, comprising the same. The photoacid generator is chemically and thermally stable and can exhibit high sen...  
WO/2019/045377A1
The present invention relates to a photo-acid generator and a chemical amplification type photoresist composition comprising the same for a thick film, wherein the photo-acid generator has, besides effects as a photo-acid generator, rema...  
WO/2019/044736A1
The present invention provides a detection method and detection probe for colibactin and colibactin-producing bacteria. The present invention provides, for example, the detection of myristoyl-asparagine using a tissue sample or stool sam...  
WO/2019/036377A1
The present disclosure provides certain tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers an...  
WO/2019/036384A1
The present disclosure provides tricyclic compounds of formula (I) that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as can...  
WO/2019/029613A1
A deuterated quinoline compound, specifically a compound represented by formula (I), a stereochemical isomer thereof, a solvate thereof or a pharmaceutically acceptable salt thereof for use in the preparation of a medicament for treating...  
WO/2019/009412A1
The present invention addresses the problem of providing a novel compound having high LSD1 inhibitory activity, high selectivity for LSD1 inhibition, and/or having useful therapeutic effects for various diseases. One embodiment of the pr...  
WO/2018/236125A1
The present invention relates to a method for converting, into aconine, diester-diterpenoid alkaloids and monoester-diterpenoid alkaloids that are highly toxic substances contained in Aconitum carmichaeli Debeaux or Aconite tuber, and a ...  
WO/2018/212355A1
The fluorescent compound is represented by general formula (I) or (II). In general formulas (I) and (II), R1 and R11 represent an alkyl group or ω-aminoalkyl group; R2 and R12 represent a hydrogen atom or alkyl group; R3 and R13 represe...  
WO/2018/206078A1
The present invention concerns cocrystals of finasteride and a carboxylic acid, a method of their preparation and a pharmaceutical formulation comprising said cocrystals. In addition the invention relates to said cocrystals for use in th...  
WO/2018/191472A1
The presently described technology provides compositions of one or more of oxoacids, polyethylene glycols, and vitamin compounds chemically conjugated to levorphanol ((-)-17-methylmorphinan-3-ol) to form novel prodrugs and compositions o...  
WO/2018/183868A1
The present disclosure relates to compositions and methods for improving the transplantation outcome and/or reducing immune response in a subject. The compositions comprise a DNA-PK inhibitor.  
WO/2018/171684A1
Provided in the present invention are a class of 7H-azulene[1,2,3-i,j]isoquinolin-7-one compounds, a single crystal and a use thereof: a 7H-azulene[1,2,3-i,j]isoquinolin-7-one compound has a structure represented by formula (I), and the ...  
WO/2018/172852A1
The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and co...  
WO/2018/168818A1
The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them an...  
WO/2018/158438A1
The present invention relates to acridine compound of formula structure (I), and to an electron transport layer, which comprises at least one compound of formula (I), an semiconductor layer comprising at least one compound of formula (I)...  
WO/2018/153312A1
Disclosed in the present invention are an azaspiro compound and a preparation method therefor and a use thereof, relating to the field of medicinal chemistry. The azaspiro compound having the structural characteristics of formula (I) of ...  
WO/2018/145550A1
Disclosed is an aza-spirobifluorene derivative characterized by the following structural formula: formula (1), where only one of X1, X2, X3, and X4 is a nitrogen atom while the other three are carbon atoms, R is an aromatic or heteroarom...  
WO/2018/136654A1
Disclosed herein are methods for N-demethylating an N-methylated compound using an enzymatic reaction, rather than, e.g. a chemical modification. Also provided herein are enzymes for performing the reaction.  
WO/2018/136794A1
The present disclosure relates to an optical luminescence dual sensor comprising a polymerized form of a probe for sensing pH; a polymerized form of a probe for sensing oxygen; a polymerized form of an internal reference probe; and a mat...  
WO/2018/128798A1
Novel antagonists of toll-like receptor 4 (TLR-4) are provided. More specifically, the novel antagonists of TLR-4 are derived from morphinan. Further, use of said morphinan derivatives in the treatment of diseases and/or disorders mediat...  
WO/2018/108064A1
Disclosed are a fourth generation (T790M/C797S mutation) of an EGFR kinase inhibitor, i.e. a spiro-aryl-phosphorous-oxygen compound, in particular a compound as represented by formula (I) and a pharmaceutically acceptable salt thereof, u...  
WO/2018/110399A1
The objective of the present invention is to provide a non-ionic photoacid generator having high photosensitivity to an i-line, and excellent heat-resistance stability, solubility in hydrophobic materials, and alkali developability. The ...  
WO/2018/111315A1
Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein ...  
WO/2018/106200A1
The present invention relates to a novel drug molecules formula (I), a novel method for use in preparation of said drug molecules and use of said drug molecules for preparation of a pharmaceutical composition for use in treatment of vira...  
WO/2018/103058A1
Compounds of formula (I') and methods of their use and preparation, as well as compositions comprising compounds of formula (I').  
WO/2018/099846A1
The present invention relates to compounds, comprising at least one structural element with at least three fused aromatic or heteroaromatic rings (AR) and at least one structural element with an aromatic or heteroaromatic valerolactam (A...  
WO/2018/099432A1
The present invention relates to a fused ring compound and a preparation method and application thereof. The fused ring compound is represented by general formula (I). The fused ring compound emits fluorescence at a short wavelength, and...  
WO/2018/095388A1
An organic compound, applications thereof, an organic mixture, and an organic electronic device. The structure of the organic compound is represented by general formula (1), and definitions of substituent groups in the general formula (1...  
WO/2018/083053A1
The present invention relates to fluoranthenyl-amine compounds according to a formula (I). Said compounds are suitable for use in electronic devices. The invention also relates to a method for producing said compounds, and to electronic ...  
WO/2018/083171A1
The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.  
WO/2018/081343A1
Provided are novel compounds of Formula (I or Ia'): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compo...  
WO/2018/068696A1
Disclosed are PEGylated sinomenine and derivative thereof and a preparation method and use of the same. The PEGylated sinomenine or derivative thereof can significantly reduce immunogenic reactions or allergic reactions, extend the half-...  
WO/2018/065924A1
The present invention relates to intermediates of Mitogen-activated protein kinase kinase (MAP2K or MEK) inhibitors such as Selumetinib, Binimetinib and process for their preparation. The present invention also relates to process for the...  
WO/2018/048247A1
The present specification relates to a compound and an organic electronic element comprising the same.  
WO/2018/038401A1
The present invention relates to a novel compound and an organic electroluminescence device including same. The compound according to the present invention may be used in an organic material layer of an organic electroluminescence device...  
WO/2018/029137A1
The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.  
WO/2018/012845A1
The present application relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.  
WO/2018/009488A1
The application describes methods for making a deuterated dextromethorphan of Formula (I), deuterated dextromethorphan produced by these methods, and pharmaceutically acceptable salts thereof.  
WO/2018/009007A1
The present application provides: a heterocyclic compound capable of greatly improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light emitting device; and an organic light emitting device h...  
WO/2018/009009A1
The present application provides a heterocyclic compound capable of remarkably improving the lifespan, efficiency, electrochemical stability, and thermal stability of an organic light-emitting device, and an organic light-emitting device...  
WO/2018/005731A1
A lactam-functionalized polymer is disclosed. The lactam-functionalized polymer includes lactam-functionalized polyacetal polyether, polyhemiaminal polyether or polyaminal polyether. The applications of the lactam-functionalized polymer ...  
WO/2017/223229A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2017/218191A1
The present invention includes compounds, compositions and methods that are useful for preventing or treating melanoma or any other Myc-expressing cancer in a subject. In certain embodiments, the compounds comprise estrogen (including es...  
WO/2017/218950A1
The present invention is directed to inhibitors of histone deacetylases (HDACs) such as HDAC6, and their use in the treatment of diseases such as cell proliferative diseases (e.g., cancer), neurological (e.g., neurodegenerative disease o...  
WO/2017/197045A1
A highly convergent biomimetic synthesis of a complex polycyclic scaffold has been successfully implemented. From these efforts, compounds having a structure of Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer ...  
WO/2017/176510A1
An electro-polarizable compound has a general formula: (I) Core1 is an aromatic polycyclic conjugated molecule. R1 and R1' are electron donor and acceptor groups, respectively; m, m' can be 0, 1, 2, 3, 4, 5, 6, but not m=m'=0. R2 is an i...  

Matches 251 - 300 out of 4,648